Ambassador Deborah Birx, MD, answers the persistent question of whether mRNA technology is safe in the long term.
Since the start of the COVID-19 pandemic, there have been ongoing discussions and examinations of the messenger RNA (mRNA) technology. However, both the public and healthcare workers still have questions.
Katalin Karikó, PhD, and Drew Weissman, MD, PhD, invented the messenger mRNA technology at Penn Institute, Philadelphia, Pennsylvania, in the 1990s. There are several more mRNA vaccines in development, including HIV, influenza, respiratory syncytial virus, Zika virus, cytomegalovirus, and cancer. Others are vaccines for individuals with severe allergies, such as dust mites or peanut allergies, heart attack and stroke, genetic diseases, and neurodevelopmental disorders.
How does mRNA technology work? According to History of Vaccines.org, “The messenger RNA (mRNA) takes the code to the ribosome where the protein is put together. That final protein is what then leaves the cell. In the case of an mRNA vaccine, the vaccine delivers the mRNA to the ribosome (not the nucleus, where DNA is housed), and a protein that looks just like the virus protein is created. When that protein leaves the cell, the immune system recognizes it as a viral protein and goes to work creating antibodies against it.”
Although mRNA technology has been studied since the early 1990s, some individuals still have concerns about its efficacy and safety. Speaking with Infection Control Today®, Ambassador Deborah Birx, MD, a Senior Fellow at the George W. Bush Institute in Dallas, Texas, addresses the question of the long-term safety of mRNA vaccine technology.
“Across the world, billions [of people] have been immunized, Birx said. “So we know about [mRNA’s] acute safety profile. We can definitively say that mRNA technology that is utilized to express this spike protein is very safe in the first 4 years. What people may have questions about is, do we know—definitively—that it's safe 2 decades from now, 3 decades from now? That database is smaller; it's really limited to people who may have gotten the Ebola vaccine. They're now probably a decade out.”
Birx continued, “I know the FDA is committed to making sure that they're studying the long-term consequences of this particular vaccine…. The questions are good. And what we can say, legitimately, as scientists that have developed vaccines, is we don't see anything concerning in the first 4 years of delivery. But again, that gets back to the point of being very clear as to who can benefit from a vaccine, particularly this vaccine. And I think we should recognize that people have definitive questions. That's why we [scientists and the CDC] should be putting out very clearly who should be immunized and the frequency to which those people should be immunized.”
(Quotes have been edited for clarity.)
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.